Dashboard
Manage Tickers

SLS


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

sellas-life-sciences-group-announces-exercise-of-warrants-to-purchase-up-to-22363714-shares-for-gross-cash-proceeds-31m
SELLAS Life Sciences Group Announces Exerc...
10/27/2025 12:50:27

sellas-life-sciences-gr-option-alert-feb-20-25-calls-sweep-37-near-the-ask-6320--0601-vs-0-oi-earnings-1112-after-close-est-ref2
SELLAS Life Sciences Gr Option Alert: Feb ...
10/14/2025 15:43:48

sellas-life-sciences-to-present-preclinical-efficacy-of-highly-selective-cdk9-inhibitor-sls009-as-monotherapy-and-in-combination-with-venetoclax-in-t-cell-prolymphocytic-leukemia-at-esmo-congress-2025
SELLAS Life Sciences To Present Preclinica...
10/13/2025 12:09:38

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharma...

sellas-life-sciences-group-files-for-offer-and-resale-by-selling-stockholders-up-to-19685040-shares-of-common-stock
SELLAS Life Sciences Group Files For Offer...
10/10/2025 20:13:07

https://www.sec.gov/Archives/edgar/data/1390478/000110465925098711/tm2528102d1_s3.htm

sellas-life-sciences-group-announces-exercise-of-warrants-held-by-institutional-investor-to-purchase-up-to-19685040-shares-for-gross-proceeds-236m
SELLAS Life Sciences Group Announces Exerc...
09/11/2025 12:36:41

sellas-life-sciences-gr-option-alert-jan-2027-25-calls-sweep-97-near-the-ask-1155--0451-vs-8362-oi-ref1785
SELLAS Life Sciences Gr Option Alert: Jan,...
08/20/2025 14:02:33

sellas-life-sciences-gr-q2-eps-007-beats-008-estimate
SELLAS Life Sciences Gr Q2 EPS $(0.07) Bea...
08/12/2025 20:28:44

SELLAS Life Sciences Gr (NASDAQ:SLS) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate o...

sellas-life-sciences-announces-independent-data-monitoring-committee-recommended-to-continue-phase-3-regal-trial-without-modification
SELLAS Life Sciences Announces Independent...
08/07/2025 12:33:59

maxim-group-maintains-buy-on-sellas-life-sciences-gr-raises-price-target-to-7
Maxim Group Maintains Buy on SELLAS Life S...
07/16/2025 18:32:09

Maxim Group analyst Jason McCarthy maintains SELLAS Life Sciences Gr (NASDAQ:SLS) with a Buy and raises the price target fro...

sellas-life-sciences-says-phase-2-trial-of-sls009-tambiciclib-met-all-primary-endpoints-in-relapsedrefractory-acute-myeloid-leukemia
Sellas Life Sciences Says Phase 2 Trial Of...
07/15/2025 11:47:14

The Trial Exceeded Target Overall Response Rate (ORR) of 20%, with 44% Response Rate Among Patients with Acute Myeloid Leukemia...

sellas-life-sciences-to-be-added-to-russell-3000-and-russell-2000-indexes-effective-june-27-as-part-of-2025-russell-indexes-annual-reconstitution
SELLAS Life Sciences To Be Added To Russel...
06/24/2025 12:01:14

sellas-life-sciences-doses-first-pediatric-aml-patient-in-ongoing-phase-2-trial-of-sls009-rr-aml
SELLAS Life Sciences Doses First Pediatric...
05/15/2025 12:51:11

sellas-life-sciences-gr-q1-eps-007-beats-010-estimate
SELLAS Life Sciences Gr Q1 EPS $(0.07) Bea...
05/13/2025 20:30:55

SELLAS Life Sciences Gr (NASDAQ:SLS) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate o...

sellas-life-sciences-presents-preclinical-efficacy-of-sls009-in-tp53-mutated-aml-cells-at-aacr-conference
Sellas Life Sciences Presents Preclinical ...
04/28/2025 12:47:52

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceuti...

sellas-life-sciences-group-announced-cohort-3-data-from-ongoing-phase-2-trial-of-sls009-in-rr-aml
SELLAS Life Sciences Group Announced Cohor...
04/08/2025 12:50:11

sellas-life-sciences-gr-fy-2024-gaap-eps-050-beats-054-estimate
SELLAS Life Sciences Gr FY 2024 GAAP EPS $...
03/20/2025 20:15:58

sellas-announces-data-from-phase-2a-trial-of-sls009-in-combination-with-zanubrutinib-in-dlbcl-combination-achieved-a-67-of-overall-response-rate-median-overall-survival-not-reached-yet-67-of-patients-still-alive
SELLAS Announces Data From Phase 2a Trial ...
02/20/2025 13:47:00

- Combination Achieved a 67% of Overall Response Rate, More than Double that of Zanubrutinib Alone; 83% Disease Control Rate in...

sellas-life-sciences-group-announces-25m-registered-direct-offering-of-19685040-shares-of-its-common-stock-and-warrants-to-purchase-up-to-an-aggregate-of-19685040-shares-of-common-stock-in-a-registered-direct-offering-at-a-combined-purchase-price-of-127-per-share-and-accompanying-warrant
SELLAS Life Sciences Group Announces $25M ...
01/28/2025 20:13:18

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceuti...

sellas-life-sciences-ceo-dr-angelos-stergiou-to-appear-on-fox-business-at-150-pm-et
SELLAS Life Sciences CEO Dr. Angelos Sterg...
01/24/2025 16:41:24

https://x.com/SellasLife/status/1882827755298918684

sellas-life-sciences-shares-are-trading-higher-after-the-company-announced-interim-analysis-results-from-its-phase-3-regal-trial-of-gps-in-acute-myeloid-leukemia
Sellas Life Sciences shares are trading hi...
01/23/2025 13:17:34

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION